ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / ANIK / dividends
INFU (77) TMCI (36) OSUR (31) PROF (40) ⌘ Pro Terminal β†’

Anika Therapeutics Inc. (ANIK) Dividend Safety Gauge & 10-Year DRIP Compounder

$20.95 -3.85% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $20.77

Anika Therapeutics Inc. (ANIK) carries a Roarable Rating of D+ (Sell) with 53/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

πŸ“Š Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY) β†’
ROARABLE D+ β€’ SELL / AVOID Cap $280.4M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ANIK Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is ANIK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Anika Therapeutics Inc. (NASDAQ: ANIK) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $20.95 (-3.85% 1D, market cap $280.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, ANIK ranks #236 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does ANIK compare to INFU and TMCI in the Health Care sector?
β–Ό

Within the Health Care sector (Medical/Dental Instruments), ANIK carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of 56.6%, and ROIC of -10.2%. By comparison, INFU (InfuSystems Holdings Inc.) holds a B+ grade (77/100 RQD, P/E 43.4x, ROIC 12.8%, cap $280.2M) and TMCI (Treace Medical Concepts Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -32.4%, cap $288.1M). Among the 5-stock peer group, INFU leads on earnings multiple (43.4x) while INFU leads on capital efficiency (12.8% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ANIK?
β–Ό

Per ANIK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000898437), Anika Therapeutics Inc. generated $112.8M in revenue (-5.9% YoY), -$11.0M in net income, and $4.4M in free cash flow against $190.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $20.77 (-0.88%)🧬 Dilution Drag (+1.36% YoY Shares)βš™οΈ Cash Engine: 12/20 (C-) β€’ 3.9% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 53/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.9% avg 90D alpha vs SPY β€’ 50.6% hit rate β€” wait for RQD β‰₯ 70 breakout).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D+
025507510053
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ Β· Rk D+
Cash (12)Whales (12)SEC (11)Macro (11)CEO (7)
Each axis scored 0–20
12M PRICE TARGET CONE-2.2% Base Target
$24 Bull$20 Base$16 Bear
πŸ“¬ FREE ANIK RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for ANIK)Realized 20D OHLCV Swing Band: Β±7.9%
Deterministic 5-Pillar Attribution (53/100 Composite)
πŸ” WHY ANIK SCORES 53/100 (D+) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Cash Engine Quality+12/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 3.9% FCF Margin ($4.4M FCF) & 56.6% Gross Margin

β–² #2 Bullish Driver: Whale & Options Positioning+12/20 pts (23% of score)

20D Institutional Volume Accumulation (Β±7.9% realized swing band)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution7/20 pts (-13 pt drag)

Dilution Drag (+1.36% YoY Shares) & executive Form 4 sales trim 13 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
45
Grade D$20.53-0.4% Next Q
Q2 (-2Q)
48
Grade D$20.44+4.5% Next Q
Q3 (-1Q)
50
Grade C-$21.35-1.9% Next Q
Current
53
Grade D+$20.95-0.9% Hist 90D Ξ±
Trajectory: D (45) β†’ D+ (53)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a ANIK Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While ANIK currently carries a cautious 53/100 (D+) rating due to Insider Conviction & Share Dilution (7/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($20.66) and Max Pain ($22.00) forces dealer call-delta covering toward $24.17.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ANIKβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œANIK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 53%NO 47%Trade / Inspect Odds β†’
CASH DIVIDEND + BUYBACK YIELD
0.6% Total Yield
0% Cash ($0.00/yr) + 0.6% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 β€’ REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years β†’ $17,081

Est. Year-10 Shareholder Yield: $102/yr
$10.6K
Yr 1
$11.1K
Yr 2
$11.7K
Yr 3
$12.4K
Yr 4
$13.1K
Yr 5
$13.8K
Yr 6
$14.5K
Yr 7
$15.3K
Yr 8
$16.2K
Yr 9
$17.1K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ANIK)

  • βœ“Walkthrough of ANIK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
ANIK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +43.99%πŸ“ WEDGE COMPRESSION COIL
2026-11-03O $21.79H $21.79L $20.95C $20.95VOL 66.7K
RES: $21.80SUP: $19.40SMA50: $20.66SMA200: $16.19
$23.73$20.20$16.67$13.14$9.61RES $21.80SUP $19.40$20.952026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ANIK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ ANIK Butterfly Map β†’ + Track ANIK β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. -5.9% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ANIK today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for ANIK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ANIK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ANIK)

Health Care Rank #236 of 1016 βš”οΈ INFU vs ANIK Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (ANIK vs. INFU, TMCI, OSUR, PROF)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Anika Therapeutics Inc. (ANIK) ranks #236 by composite RQD confidence (53/100, grade D+) and #524 by equity capitalization ($280.4M). Within this direct 5-issuer industry benchmark cohort, INFU leads on earnings valuation at 43.4x trailing P/E, while INFU leads on capital efficiency and profitability with 12.8% ROIC and 56.0% gross margin. INFU currently holds the highest overall quantitative score in the immediate peer group at 77/100 (B+) compared with ANIK at 53/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ANIK ACTIVE
Anika Therapeutics Inc.
D+ 53/100 β€” 56.6% -10.2% -3.85% $280.4M Benchmark Subject
INFU
InfuSystems Holdings Inc.
B+ 77/100 43.4x 56.0% 12.8% -2.63% $280.2M /infu-vs-anik β†’
TMCI
Treace Medical Concepts Inc.
D- 36/100 β€” 79.8% -32.4% -12.45% $288.1M /tmci-vs-anik β†’
OSUR
OraSure Technologies Inc.
E 31/100 β€” 41.9% -35.0% -3.43% $271.7M /osur-vs-anik β†’
PROF
Profound Medical Corp.
D- 40/100 β€” 70.8% -35.0% +12.12% $240.0M /prof-vs-anik β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0000898437

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Anika Therapeutics Inc. (ANIK) reported GAAP revenue of $112.8M (-5.9% vs. FY2024 revenue of $119.9M , and -6.6% cumulative change since FY2023) , GAAP net income of -$11.0M, operating cash flow of $11.2M, and free cash flow of $4.4M (+287.1% YoY). On the balance sheet, ANIK closed FY2025 with $190.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $112.8M -$11.0M $11.2M $4.4M $190.3M β€”
FY2024 (FY) 2024-12-31 $119.9M -$56.0M $5.4M -$2.3M $202.7M β€”
FY2023 (FY) 2023-12-31 $120.8M -$83.0M -$1.8M -$1.8M β€” β€”

3. ANIK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ANIK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Anika Therapeutics Inc. (NASDAQ: ANIK) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 53/100 at a spot price of $20.95 (-3.85% 1D, market cap $280.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, ANIK ranks #236 in composite RQD confidence.

How does ANIK compare to INFU and TMCI in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), ANIK carries a Roarable D+ (53/100 RQD), trailing P/E of N/A, gross margin of 56.6%, and ROIC of -10.2%. By comparison, INFU (InfuSystems Holdings Inc.) holds a B+ grade (77/100 RQD, P/E 43.4x, ROIC 12.8%, cap $280.2M) and TMCI (Treace Medical Concepts Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -32.4%, cap $288.1M). Among the 5-stock peer group, INFU leads on earnings multiple (43.4x) while INFU leads on capital efficiency (12.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ANIK?

Per ANIK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000898437), Anika Therapeutics Inc. generated $112.8M in revenue (-5.9% YoY), -$11.0M in net income, and $4.4M in free cash flow against $190.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ANIK trading relative to its 50-day, 200-day, and 52-week technical levels?

ANIK last traded at $20.95 (-3.85% on volume of 66,709 shares), positioning the stock +1.40% above its 50-day simple moving average ($20.66) and +29.40% above its 200-day simple moving average ($16.19). Across its 52-week range of $9.01 to $22.88, ANIK sits at the 86.1% percentile with a 14-day RSI of 51.8 (NEUTRAL RANGE) and an implied next-earnings move of Β±7.9% ($19.29 to $22.61).

ANIK Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Does ANIK pay a dividend and is it safe?

Anika Therapeutics Inc. (ANIK) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: ANIK RQD Cockpit ANIK 12M Forecast ANIK Earnings & Move ANIK Dividends & DRIP ANIK Insiders & 13F ANIK Whale Options ANIK Profit Sankey ANIK News & Why
ROARABLE RATING BRIEF β€’ RQD 53/100 (D+) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

ANIK β€” Anika Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:38:58Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, ANIK scores 55 out of 100, a letter grade of D+, labeled "Roarable Sell β€” Weak Fundamentals / Trim." The five pillars are: Fundamental Cash Engine 12/20 (ROIC -10.2%; FCF yield 1.5%); Whale 13F Flow 14/20 (institutional accumulation and options positioning); Insider Conviction 7/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit 11/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet 11/20 (Altman Z 2.5; Piotroski F 6/9; Debt/Equity 0.5).

For a prospective investor evaluating the stock today, the weakest pillar is insider conviction (7/20), followed by the cash engine and balance sheet (both 11–12/20). The upside case rests mainly on the institutional flow pillar (14/20) and a balance sheet that the rating describes as moderately sound (Altman Z 2.5, Piotroski F 6/9). The valuation tradeoff is that the cash engine pillar reflects a negative ROIC and a thin 1.5% FCF yield, so the current price is not supported by demonstrated returns on capital in the provided data. The rating's verdict is a trim-oriented signal, meaning the aggregated data leans negative. This is an analytical summary, not personalized financial advice.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$112.8M$-11.1M$-11.0MN/A$4.4M$57.5MN/A
FY 2024$119.9M$-5.1M$-56.0MN/A$-2.3M$55.6MN/A
FY 2023$120.8M$0.8M$-83.0MN/A$-1.8MN/AN/A

Per the SEC financials, revenue declined from $120.8M (FY 2023) to $112.8M (FY 2025), and the company reported net losses in all three periods. Per the Market Data section, operating margin and net margin are each -9.8% and ROIC is -10.2%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 6/9, with a Debt/Equity ratio of 0.5. FY 2025 free cash flow was positive at $4.4M, while FY 2024 was negative.

Recent Catalysts & News Wire Analysis

Per the recent news feed, the near-term catalyst is the scheduled release of third-quarter 2026 financial results on Friday, November 6, 2026. A TradingView item cites a Q3'26 revenue estimate of 29.44M USD, which is a headline figure only. The remaining items are a Yahoo Finance seasonal chart for Lifecore Biomedical (LFCR), a Stock Traders Daily momentum piece, and a Yahoo Finance seasonal chart for Amylyx Pharmaceuticals (AMLX). These items are labeled as market wire content and do not provide company-specific fundamental data. Per the Butterfly Supply-Chain Graph, the supply chain is recorded as "NONE," with no butterfly links and no proprietary signals.

Open Questions

  • What are the actual P/E, forward P/E, EV/EBITDA, and EPS figures, given that the source data lists them as unavailable?
  • What drove the FY 2024 net loss of $-56.0M and the FY 2023 net loss of $-83.0M, and are these one-time or recurring?
  • What is the debt balance, since the source data lists debt as N/A for every period?
  • Which products and customers generate the $112.8M of FY 2025 revenue, and what is the revenue trend outlook?
  • What were the specific institutional and insider transactions behind the 14/20 and 7/20 pillar scores?

ANIK Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Anika Therapeutics Inc. (ANIK) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to ANIK Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ANIK Bull vs. Bear Conversation Board β€” What's Your Call at $20.95?

πŸ‚ 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ANIK 🐻 50% BEARISH CONVICTION
1. Pick Your Side on ANIK:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk βš–οΈ DEBATE HOST 🎯 Target: $23.53 (+8.0%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is ANIK (D+ β€’ RQD 55/100) a Buy at $21.79?

Welcome to the ANIK (Anika Therapeutics Inc.) Roar Pit. Current RQD Composite is 55/100 (Roarable Sell β€” Weak Fundamentals / Trim) in Medical/Dental Instruments. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $17.00 (-22.0%)
Spot @ $21.79

Pump the brakes on ANIK β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on ANIK, but look at what you are paying: current EV/EBITDA multiples with 56.6% gross margins. Unless Anika Therapeutics Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

AL AlphaFlow_Cap Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $26.15 (+20.0%)
Spot @ $21.79

ANIK cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on ANIK, the market is fixating on short-term headline noise in Medical/Dental Instruments and ignoring the balance sheet and cash flow trajectory. At $21.79 (52-wk range $9.01 - $22.88), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.35 -5.42% GLD $361.65 -3.59%